纤维化驱动性肌成纤维细胞前体的鉴定揭示骨髓纤维化新的治疗途径
综述阐述骨髓纤维化中肌成纤维细胞的细胞起源,指出Gli1+与LepR+间充质基质细胞是纤维化驱动性肌成纤维细胞的前体;小鼠模型中遗传去除Gli1+细胞或药物靶向Hh-Gli信号可改善纤维化,干预Pdgfrα信号可抑制LepR+基质细胞扩增并改善骨髓纤维化;直接靶向Gli蛋白可能成为骨髓纤维化的新治疗策略。
要点
- Gli1+与LepR+间充质基质细胞是骨髓纤维化中肌成纤维细胞的前体。
- 小鼠模型中遗传去除Gli1+细胞或药物靶向Hh-Gli信号可改善纤维化。
- 直接靶向Gli蛋白可能成为骨髓纤维化的新治疗途径。
核心结论
- 恶性造血克隆来源的巨核细胞在重编程骨髓纤维化造血干细胞龛中起核心作用,可能对异基因干细胞移植后的造血重建产生不利影响。
- 直接靶向Gli蛋白可能是一种有趣且新颖的骨髓纤维化治疗途径。
研究设计与样本
- 综述,聚焦骨髓纤维化中肌成纤维细胞的细胞起源与分子机制及治疗靶点。
主要发现
- Gli1+与LepR+间充质基质细胞是骨髓中纤维化驱动性肌成纤维细胞的前体。
- 小鼠骨髓纤维化模型中遗传去除Gli1+间充质基质细胞或药物靶向Hh-Gli信号可改善纤维化。
- 药物或遗传干预LepR+基质细胞中的Pdgfrα信号可抑制其扩增并改善骨髓纤维化。
- 直接靶向Gli蛋白可抑制Gli1+细胞增殖与肌成纤维细胞分化,从而减轻纤维化严重程度并改善器官功能。
- 经典Hh抑制(如Smo抑制)未能改善肺纤维化、肾纤维化或骨髓纤维化,而直接抑制Gli蛋白可改善纤维化。
临床怎么用
- 作者认为直接靶向Gli蛋白可能是一种有趣且新颖的骨髓纤维化治疗途径。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Myofibroblasts are fibrosis-driving cells and are well characterized in solid organ fibrosis, but their role and cellular origin in bone marrow fibrosis remains obscure. Recent work has demonstrated that Gli1+ and LepR+ mesenchymal stromal cells (MSCs) are progenitors of fibrosis-causing myofibroblasts in the bone marrow. Genetic ablation of Gli1+ MSCs or pharmacologic targeting of hedgehog (Hh)-Gli signaling ameliorated fibrosis in mouse models of myelofibrosis (MF). Moreover, pharmacologic or genetic intervention in platelet-derived growth factor receptor α (Pdgfrα) signaling in Lepr+ stromal cells suppressed their expansion and ameliorated MF. Improved understanding of cellular and molecular mechanisms in the hematopoietic stem cell niche that govern the transition of MSCs to myofibroblasts and myofibroblast expansion in MF has led to new paradigms in the pathogenesis and treatment of MF. Here, we highlight the central role of malignant hematopoietic clone-derived megakaryocytes in reprogramming the hematopoietic stem cell niche in MF with potential detrimental consequences for hematopoietic reconstitution after allogenic stem cell transplantation, so far the only therapeutic approach in MF considered to be curative. We and others have reported that targeting Hh-Gli signaling is a therapeutic strategy in solid organ fibrosis. Data indicate that targeting Gli proteins directly inhibits Gli1+ cell proliferation and myofibroblast differentiation, which results in reduced fibrosis severity and improved organ function. Although canonical Hh inhibition (eg, smoothened [Smo] inhibition) failed to improve pulmonary fibrosis, kidney fibrosis, or MF, the direct inhibition of Gli proteins ameliorated fibrosis. Therefore, targeting Gli proteins directly might be an interesting and novel therapeutic approach in MF.
引用
- Kramann R, Schneider RK. The identification of fibrosis-driving myofibroblast precursors reveals new therapeutic avenues in myelofibrosis. Blood. 2018. PMID: 29572380. doi:10.1182/blood-2018-02-834820
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。